
Pediatric Growth Hormone Deficiency - Pipeline Insight, 2024
Description
Pediatric Growth Hormone Deficiency - Pipeline Insight, 2024
DelveInsight’s, “Pediatric Growth Hormone Deficiency - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Pediatric Growth Hormone Deficiency pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Pediatric Growth Hormone Deficiency: Overview
Growth hormone deficiency (GHD) is caused when the pituitary gland or the hypothalamus is not functioning properly and does not produce enough growth hormone. GHD can be acquired or congenital. Children with GHD have abnormally short stature with normal body proportions. GHD affects male and female equally. Symptoms include slow growth, delayed sexual development, and others.
""Pediatric Growth Hormone Deficiency - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pediatric Growth Hormone Deficiency pipeline landscape is provided which includes the disease overview and Pediatric Growth Hormone Deficiency treatment guidelines. The assessment part of the report embraces, in depth Pediatric Growth Hormone Deficiency commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pediatric Growth Hormone Deficiency collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Pediatric Growth Hormone Deficiency R&D. The therapies under development are focused on novel approaches to treat/improve Pediatric Growth Hormone Deficiency.
This segment of the Pediatric Growth Hormone Deficiency report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Pediatric Growth Hormone Deficiency Emerging Drugs
- Lonapegsomatropin: Ascendis Pharma A/S
- Somatrogon: OPKO Health
Further product details are provided in the report……..
Pediatric Growth Hormone Deficiency: Therapeutic Assessment
This segment of the report provides insights about the different Pediatric Growth Hormone Deficiency drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Pediatric Growth Hormone Deficiency
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Pediatric Growth Hormone Deficiency: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Pediatric Growth Hormone Deficiency therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pediatric Growth Hormone Deficiency drugs.
Pediatric Growth Hormone Deficiency Report Insights
- Pediatric Growth Hormone Deficiency Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Pediatric Growth Hormone Deficiency drugs?
- How many Pediatric Growth Hormone Deficiency drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pediatric Growth Hormone Deficiency?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Pediatric Growth Hormone Deficiency therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Pediatric Growth Hormone Deficiency and their status?
- What are the key designations that have been granted to the emerging drugs?
- Ascendis Pharma
- OPKO Health
- Aravive
- Lonapegsomatropin
- Somatrogon
- VRS-317
Table of Contents
40 Pages
- Introduction
- Executive Summary
- Pediatric Growth Hormone Deficiency: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Pediatric Growth Hormone Deficiency – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Pediatric Growth Hormone Deficiency companies’ collaborations, Licensing, Acquisition -Deal Value Trends
- Pediatric Growth Hormone Deficiency Collaboration Deals
- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis
- Late Stage Products (Phase Pre-registration)
- Comparative Analysis
- Lonapegsomatropin: Ascendis Pharma
- Product Description
- Research and Development
- Product Development Activities
- Late Stage Products (Phase III)
- Comparative Analysis
- Somatrogon: OPKO Health
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Pediatric Growth Hormone Deficiency Key Companies
- Pediatric Growth Hormone Deficiency Key Products
- Pediatric Growth Hormone Deficiency- Unmet Needs
- Pediatric Growth Hormone Deficiency- Market Drivers and Barriers
- Pediatric Growth Hormone Deficiency- Future Perspectives and Conclusion
- Pediatric Growth Hormone Deficiency Analyst Views
- Pediatric Growth Hormone Deficiency Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.